NewLink Genetics to Host Its Third Quarter 2016 Financial Results Conference Call on November 1, 2016
October 24 2016 - 7:00AM
NewLink Genetics Corporation (NASDAQ:NLNK), today reported that it
will release its third quarter 2016 financial results on Tuesday,
November 1, 2016. The company has scheduled a conference call for
8:30 AM ET the same day to discuss the results and to give an
update on clinical and business development activities.
NewLink Genetics' senior management team will
host the conference call, which will be open to all listeners.
There will also be a question and answer session following the
prepared remarks.
Access to the live conference call is available by dialing (855)
469-0612 (U.S.) or (484) 756-4268 (international) five minutes
prior to the start of the call. The conference call will be webcast
live and a link can be accessed through the NewLink
Genetics website at http://edge.media-server.com/m/p/8diprai2.
A replay of the call will be available for two weeks from the date
of the call and can be accessed by dialing (855) 859-2056 (U.S.) or
(404) 537-3406 (international) and using the passcode 5960440.
About NewLink Genetics
Corporation
NewLink Genetics is a biopharmaceutical company at the forefront
of discovering, developing and commercializing novel
immuno-oncology product candidates, including both cellular
immunotherapy and checkpoint inhibitor platforms, to improve the
lives of patients with cancer. NewLink Genetics’ portfolio includes
biologic and small molecule immunotherapy product candidates
intended to treat a wide range of oncology indications. NewLink
Genetics’ product candidates are designed to harness multiple
components of the immune system to combat cancer. For more
information, please visit http://www.newlinkgenetics.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking
statements of NewLink Genetics that involve substantial
risks and uncertainties. All statements, other than statements of
historical facts, contained in this press release are
forward-looking statements, within the meaning of The Private
Securities Litigation Reform Act of 1995. The words "anticipate,"
"believe," "estimate," "expect," "intend," "may," "plan," "target,"
"potential," "will," "could," "should," "seek" or the negative of
these terms or other similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. These forward-looking
statements include any statements other than statements of
historical fact. Actual results or events could differ materially
from the plans, intentions and expectations disclosed in the
forward-looking statements that NewLink Genetics makes
due to a number of important factors, including those risks
discussed in "Risk Factors" and elsewhere in NewLink Genetics'
Annual Report on Form 10-K for the year ended December 31,
2015 and other reports filed with the U.S. Securities and
Exchange Commission (SEC). The forward-looking statements in this
press release represent NewLink' Genetics' views as of the date of
this press release. NewLink Genetics anticipates that
subsequent events and developments will cause its views to change.
However, while it may elect to update these forward-looking
statements at some point in the future, it specifically disclaims
any obligation to do so. You should, therefore, not rely on these
forward-looking statements as representing NewLink Genetics' views
as of any date subsequent to the date of this press release.
Corporate Contact:
Jack Henneman
Chief Financial Officer
(515) 598-2561
Investor@linkp.com
Media and Investor Contacts:
Media
Ben Navon
LaVoieHealthScience
617-374-8800, ext. 108
bnavon@lavoiehealthscience.com
Investors
Beth Kurth
LaVoieHealthScience
617-374-8800, ext. 106
bkurth@lavoiehealthscience.com
NewLink Genetics (NASDAQ:NLNK)
Historical Stock Chart
From Mar 2024 to Apr 2024
NewLink Genetics (NASDAQ:NLNK)
Historical Stock Chart
From Apr 2023 to Apr 2024